Why the study?
Existing 2017 ESC/EACTS guideline recommendations on antithrombotic therapy in patients undergoing TAVI were mostly based on expert opinion, despite persistent thromboembolic and bleeding complications.
What is the optimal antithrombotic therapy during and after transcatheter aortic valve implantation?
What is the optimal antithrombotic therapy during and after transcatheter aortic valve implantation?
This consensus document provides updated recommendations for antithrombotic management in patients undergoing TAVI, incorporating recent trial data to update previous expert-opinion-based guidelines.
Updated TAVI antithrombotic recommendations should now guide practice; extends prior expert-opinion guidelines with recent RCT data.
Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.
No takes yet. Share an insight, caveat, or question.
Berg et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: